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1. Introduction 
Arterial hypotension is one of the most common 
clinical findings following severe bites by the North 
American rattlesnakes [I] . As has been indicated by 
Russell et al. [2] the immediate and profound decrease 
in systemic arterial pressure can not be attributed to 
direct cardiac effects since neither the heart rate nor 
the force of contraction are directly altered by 
intravenous administration of Crotalus venoms to a 
wide variety of experimental animals. 
Indirect evidence for the potential role of brady- 
kinin in snake venom-induced hypotension has been 
reported by Russell [3] who showed decreased 
bradykininogen levels in three patients following 
rattlesnake bites. Only one of the patients, however, 
was reported to be in shock when reporting to the 
hospital while the other two were normotensive and/or 
slightly hypotensive. It is obvious, then, that because 
of the great complexity of the venom secretion from 
the rattlesnakes little is known about the specific 
components which may induce the profound fall in 
blood pressure following envenomation. 
In this paper the isolation of a potent hypotensive 
peptide* (heretofore called hypotensin) from the 
venom of the Western diamondback rattlesnake 
(CFotalus &0x), its amino composition, terminal 
residues and some of its biological properties are 
reported. 
*Hypatensin: patent pending, Elars Bioresearch Laboratories, 
Inc., Fort Collins, Colorado 80522. 
North-Holland Publishing Company - Amsterdam 
2. Materials and methods 
2.1. Materials 
Western diamondback rattlesnake (C atrox) 
venom was collected from healthy specimens kept in 
our laboratory under controlled conditions of 
temperature, humidity and lighting. Immediately 
following collection the venom was cleared by 
centrifugation, lyophilized and stored at -40°C as 
described in earlier publications [4,5]. 
All chemical reagents were the best commercially 
available analytical grade; hydrochloric acid and 
other reagents for amino acid analysis were sequanal 
grade from Pierce Chemical Company; Sephadex gel 
filtration media from Pharmacia. 
2.2. Gel filtration on Sephadex G-l 00 
Venom (S- 10 g) was dissolved in 50- 100 ml of 
0.12 M Tris-HCl-0.2 M NaCl, pH 8.6, centrifuged at 
20 000 rev/min for 30 min in a refrigerated centrifuge 
(4°C) Sorval S-34 rotor. The supernatant fraction 
was then applied to a 5.0 X 100 cm column of 
Sephadex G-100 using upward flow adaptors (actual 
bed height: 90 cm) and elution carried out with the 
same buffer. 
2.3. Differential ultrafiltration 
Amicon PM-10 and UM-2 ultrafdtration membranes 
were used for further purification of the hypotensive 
peptide. 
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2.4. Gel filtration on Sephadex G-25 3. Results 
The retentate (lo- 15 ml) from the UM-2 ultra- 
filtration step was gel filtered on a 2.5 X 100.0 cm 
column of Sephadex G-25 (fine) using 0.005 M Tris- 
HCl, 0.1 M NaCl, pH 8.0. 
2.5. Amino acid analysis 
Amino acid analyses in duplicate were carried out 
on homogeneous amples of the hypotensive peptide 
according to the method originally described by 
Spackman, Stein and Moore [6] using a Durrum 
analyzer model D-500 with built in computer. Salt- 
free samples were prepared by exhaustive diafiltration 
(UM-2) against double-distilled deionized water. 
Gel filtration on Sephadex G-100 resolved the 
crude venom into five subfractions (fig.l) which have 
been partially identified [ 151 as follows: fraction I A, 
a large mol. wt. fraction excluded from the column 
contains most of the 5’nucleotidase activity and 
other unidentified components; fraction I B, contains 
the L-amino acid oxidase, phosphodiesterase, some 
remnant 5’nucleotidase activity and other components. 
Aliquots were hydrolyzed in duplicate for 24,48 
and 96 h at 110°C and the results averaged. Trypto- 
phane content was obtained from analysis of a 48 h 
alkaline hydrolyzate [7] and cysteine by performic 
acid oxidation followed by 24 h acid hydrolysis as 
described by Hirs [8]. 
Subfractions II A and II B contain all of the phos- 
pholipase-A activity, the bulk of the proteolytically 
active proteins, the hemorrhagic components of the 
venom and the myocardial depressor protein [ 151. 
Fraction III contains the small molecular weight com- 
ponents of the venom including the hypotensive 
peptide described in this work. 
3.2. Differential ultrafiltration 
2.6. N- and C-terminal residue determinations 
Amino terminal sequence was determined using 
the manual method of Petersen et al. [9] and the 
automatic sequenator method as described by 
Hermodson et al. [lo]. The carboxyl-terminal 
residue was determined following enzymatic digestion 
with carboxypeptidase-A using the Durrum analyzer. 
Fraction III was pooled and subjected to ultra- 
filtration on a PM-10 membrane; the resulting ultra- 
filtrate mol. wt. below approx. 10 000) was dialyzed 
and ultrafiltered (diafiitration) using a UM-2 Amicon 
membrane. The retentate obtained after this procedure 
was then gel filtered on a Sephadex G-25 (fine) column. 
3.3. Sephadex G-2.5 gel filtration 
Fig.2 shows the elution profile obtained when the 
2.7. Polyacrylamide electrophoresis 
Electrophoresis in 14% polyacrylamide acidic gels 
containing 6 M urea was performed as described 
earlier [4,5,1 l] without modification. 
2.8. Bioassay 
The hypotensive activity of the venom peptide 
was studied in anesthetized beagle dogs (8- 15 kg). 
A detailed investigation of the cardiovascular effects 
of varying doses of the peptide was carried out 
following a left and right heart catheterization as 
described in earlier communications [ 12,131 from 
this laboratory. The complete cardiovascular effects 
of the venom hypotensive peptide do not fall within 
the scope of the present paper and, therefore, will be 
presented elsewhere [ 141. Its hypotensive action, 
however, is herein described. 
Fig.1. Elution profile of the gel filtration step (Sephadex 
GlOO) used in the purification of hypotensin from the 
venom of Ootalus atrox. Load: 5 g venom in 80 ml Tris-HCI 
buffer pH 8.6. The fractions pooled for further purification 
are indicated by the cross hatched area. Further details in text. 
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retentate from the UM-2 diafdtration step was gel 
filtered on a 2.5 X 100 cm column of Sephadex G-25. 
The fractions constituting the second peak were pooled 
lyophilized and stored at -40°C until needed. Prior 
to amino acid analysis the highly purified hypotensive 
peptide was subjected to exhaustive diafdtration on a 
UM-2 Amicon membrane. 
3.4. Amino acid analysis 
The results of amino acid analysis of the highly 
purified peptide are shown in table 1. These values 
I were derived from duplicate hydrolyzates at 24,48 
and 96 h. Values for serine and threonine were 
Fig.2. Chromatography of Sephadex G-100 purified hypotensin 
on Sephadex G25. The fractions demarked by the cross- 
hatched area were pooled and concentrated by lyophilization. 
extrapolated to zero time hydrolysis and that reported 
for isoleucine was the maximum value obtained. Using 
the procedures described one tryptophan and one 
Table 1 
Amino acid analysis of hypotensin 
Amino acid rmoles/mga 
Residues/molecule 
Calculatedb Nearest 
integer 
Alanine 0.080 0.86 1 
A&tine 0.091 0.98 1 
Aspartic acid 0.225 2.41 2 
Cystine/2c 0.126 1.35 1 
Glutamic acid 0.300 3.22 3 
Glycine 0.144 1.55 1 
Histidine 0.067 0.72 1 
Isoleucine 0.088 0.94 1 
Leucine 0.108 1.16 1 
Lysine 0.111 1.19 1 
Methionine 0.025 0.09 0 
Phenylalanine 0.045 0.48 0 
Proline 0.276 2.96 3 
Serined 0.107 1.15 1 
Threonined 0.084 0.90 1 
Tryptophane 0.117 1.26 1 
Tyrosine 0.046 0.49 0 
Wine 0.099 1.06 1 - 
Total Residues 20 
aAverage of: 2 values at 24 h, 1 value at 48 h, 1 value at 96 h. 
bAssuming 0.093 rmoles/residue. 
CPerformic acid oxidized prior to acid hydrolysis. 
dExtrapolated to zero time hydrolysis. 
e48-h alkaline hydrolysis. 
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cysteic acid residues per mole of peptide could be 
identified. 
3.5. NH, and COOH terminal amino acid residues 
Identical results were obtained using either manual 
or automatic procedures to detect the N-terminal 
residue, which was identified as leucine; using the 
sequenator a second passage was used to determine 
the penultimate residue which was found to be 
glutamic acid. Thus, the amino terminal sequence 
of the hypotensive peptide from C: atrox venom is: 
H-Leu--Glu- 
Among the amino acids released by enzymatic 
hydrolysis with carboxypeptidase-A, serine was the 
first one to appear followed by leucine and tyrosine. 
These results were repeated after incubation at 
30 min, 2 h and 7 h and, therefore, it is concluded 
that the hypotensive peptide isolated in this study 
consists of approximately 20 residues (Ala, Arg, 
Aspz, Cys, Glua, Gly, His, Ileu, Leu, Lys, Pros, Ser, 
Thr, Trp, Val), with leucine followed by glutamic 
acid at the amino terminal sequence. Serine is the 
C-terminal amino acid residue followed by leucine 
and tyrosine. 
3.6. Gel electrophoresis 
The electrophoretic pattern obtained with the 
purified hypotensive peptide is shown in fig.3 and 
indicates that, using the procedure herein described 
this peptide can be recovered in homogeneous or 
nearly homogeneous form. 
3.7. Bioassay of hypotensive peptide 
Table 2 shows the systemic arterial pressure 
response of anesthetized beagle dogs to 1 .O mg/kg 
intravenous injection of the purified hypotensive 
Fig.3. Polyacrylamide gel electrophoresis of (from left to right): pooled Crotulus v. viridis venom (10, 20 and 40 ~1). Pure 
0otaZus v. viridis neurotoxin (10, 20 and 40 ~1); pooled Crotulus ntrox venom (10 and 20 ~1); highly purified myocardial depressor 
protein from C atrox venom; fraction I from the Sephadex G-25 gel filtration step; pure hypotensin from C. arrox venom. 
Conditions for electrophoresis: voltage, 250 V (constant); current, 100 mA; prerun, 4 h; electrolyte, 0.37 M glycine-0.1 M Citric 
acid buffer, pH 2.9; length of separation, 4 h (3°C). Gel concentration, 14% Cyanogum-41. Migration is from top (+) to bottom (-) 
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Table 2 
Aortic arterial pressure response to hypotensin administrationa 
- 
Time (min) 
Control 5 15 20 30 45 60 80 100 
Meanb 142.7 60.5 71.7 80.0 92.5 95.5 114.0 114.5 118.0 
Standard error (i) 4.5 9.4 11.1 10.8 9.6 8.3 7.7 5.2 4.8 
-___ 
“Hypotcnsin (1.0 mg/kg) was given as an I.V. bolus injection (2.0 ml saline), through a catheter in the femoral vein. 
bArterial pressure (mm Hg) was measured with an arterial catheter advanced via the femoral artery into the abdominal aorta. 
A statham P23Db strain gauge pressure transducer coupled to a 16 channel (Electronics for Medicine) photographic oscilloscopic 
system was used to continuously monitor the arterial blood pressure. 
peptide. There was an immediate and profound 
systemic arterial hypotension evidenced by a fall 
from a control value of 142.7 f 4.5 to 60.5 + 9.4 mm 
Hg 5 min following I.V. administration of the venom 
peptide. A continuous gradual increase in the aortic 
pressure towards normal was then observed with 
vaIuesof92.5 +9.6, 114.Ok7.7 and 118.0+4.8mm 
Hg at 30,60 and 100 min respectively. Ten animals 
were used in the complete cardiovascular evaluation, 
results of which will be published elsewhere [ 141. 
4. Discussion 
The hypotensive peptide isolated in this study is of 
extreme importance for several reasons: 
(1) It induces a rapid decrease in systemic arterial 
pressure which lasts for periods of up to two hours or 
longer. 
(2) Its amino acid composition differs from that of 
bradykinin, bradykinin-like peptides and bradykinin- 
potentiating peptides isolated from natural sources. 
(3) Hypotensin has leucine at the N-terminus while 
bradykinin-potentiating peptides have pyrrolidone 
carboxylic acid and bradykinin has anginine at the 
N-terminus. 
Because of the above mentioned chemical and 
biological differences and to differentiate it from other 
well known vasoactive peptides we have named the 
hypotensive peptide from Crotalus atrox venom 
hypotensin. 
Hypotensin does not appear to be destroyed by 
lung peptidases as judged by the duration of hypoten- 
sive response in intact dogs. It is, likewise, not 
destroyed by gastrointestinal peptidases ince it 
induces a dose-dependant hypotension in normal and 
spontaneously hypertensive rats when administered by 
the oral route (Bonilla, unpublished). 
The mechanism of action of hypotensin has not 
been elucidated; however, the fact that metiamide 
and chortrimeton do not block its hypotensive action 
indicate that histamine release is not responsible for 
the blood pressure decreased [141. Other possible 
mechanisms uch is central nervous system-induced 
hypotension or fi-adrenergic blocking activity are now 
being investigated. 
In conclusion, it should be noted that hypotensin 
represents a totally new type of naturally occurring 
vasoactive peptide which is very effective in lowering 
arterial blood pressure in experimental animals. The 
rapidity of onset of hypotensive response and its 
duration warrant further investigation of structure- 
activity relations, mechanism of action, and potential 
use as an antihypertensive drug. 
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